Our faculty author, co-author and contribute to more than 1500 peer-reviewed scientific publications each year. Find their recent publications below, and filter by division.
Search the faculty directory to find an individual's list of publications.
Publications
Aggarwal, Reena, Avery Plough, Natalie Henrich, Grace Galvin, Amber Rucker, Chris Barnes, William Berry, Toni Golen, and Neel T. Shah. “The design of "TeamBirth": A care process to improve communication and teamwork during labor.” Birth 48, no. 4 (December 2021): 534–40. https://doi.org/10.1111/birt.12566.
PMID
34245054
Wagner, Andrew J., Vinod Ravi, Richard F. Riedel, Kristen Ganjoo, Brian A. Van Tine, Rashmi Chugh, Lee Cranmer, et al. “nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors.” J Clin Oncol 39, no. 33 (November 20, 2021): 3660–70. https://doi.org/10.1200/JCO.21.01728.
PMID
34637337
Shen, Y. A., J. Jung, G. D. Shimberg, F. C. Hsu, Y. S. Rahmanto, S. L. Gaillard, J. Hong, et al. “Development of small molecule inhibitors targeting PBX1 transcription signaling as a novel cancer therapeutic strategy.” Iscience 24, no. 11 (November 19, 2021). https://doi.org/10.1016/j.isci.2021.103297.
DiMarco, Ashley V., Xiaodi Qin, Brock McKinney, Nina Marie G. Garcia, Sarah C. Van Alsten, Elizabeth A. Mendes, Jeremy Force, et al. “APOBEC mutagenesis inhibits breast cancer growth through induction of T cell-mediated antitumor immune responses.” Cancer Immunol Res, November 18, 2021. https://doi.org/10.1158/2326-6066.CIR-21-0146.
PMID
34795033
Emamekhoo, Hamid, Mark R. Olsen, Bradley C. Carthon, Alexandra Drakaki, Ivor J. Percent, Ana M. Molina, Daniel C. Cho, et al. “Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.” Cancer, November 16, 2021. https://doi.org/10.1002/cncr.34016.
PMID
34784056
Dzimitrowicz, Hannah, Elizabeth Esterberg, LaStella Miles, Giovanni Zanotti, Azah Borham, and Michael R. Harrison. “Referral and adjuvant treatment patterns after nephrectomy in high-risk locoregional renal cell carcinoma.” Cancer Med, November 9, 2021. https://doi.org/10.1002/cam4.4407.
PMID
34751002
Nyrop, K. A., E. M. Damone, A. M. Deal, S. B. Wheeler, M. Charlot, B. B. Reeve, E. Basch, et al. “Patient-reported treatment toxicity and adverse events in Black and White women receiving chemotherapy for early breast cancer.” Breast Cancer Res Treat, November 5, 2021. https://doi.org/10.1007/s10549-021-06439-6.
PMID
34739658
Nebhan, Caroline A., Alessio Cortellini, Weijie Ma, Teja Ganta, Haocan Song, Fei Ye, Rebecca Irlmeier, et al. “Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.” Jama Oncol, November 4, 2021. https://doi.org/10.1001/jamaoncol.2021.4960.
PMID
34734989
George, Daniel J., Krishnan Ramaswamy, Ahong Huang, David Russell, Jack Mardekian, Neil M. Schultz, Nora Janjan, and Stephen J. Freedland. “Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.” Prostate Cancer Prostatic Dis, November 3, 2021. https://doi.org/10.1038/s41391-021-00463-9.
PMID
34732856
Tucker, Matthew D., Landon C. Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman, Emily N. Kinsey, Kristin K. Ancell, et al. “Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma.” Biomark Res 9, no. 1 (November 3, 2021): 80. https://doi.org/10.1186/s40364-021-00334-4.
PMID
34732251